ASSYSTEM : Announces the repurchase of 2 274 766 ODIRNANE for a unit price of EUR 34.50 (including accrued interest)

Not for publication, release or distribution directly or indirectly in the United States, Canada, Australia or Japan. This press release is not an offer of securities, or a solicitation for purchase, subscription or sale of securities in the United States or in any other jurisdiction in which it would be unlawful to do so.

Assystem announces the repurchase of 2,274,766 ODIRNANE for a unit price of EUR 34.50 (including accrued interest) in the context of the repurchase offer

PARIS - 10 October 2016 - Following the reverse bookbuilding process conducted from 26 to 27 September 2016 (the " Repurchase Proposal "), Assystem (the " Company ") actually repurchased 2,833,281 ODIRNANE, representing circa 50.6% of the net share settled bonds with an indefinite term convertible into new shares and/or exchangeable for existing shares issued by the Company on July 9, 2014 (the " ODIRNANE "), ISIN code: FR0012032712, initially issued.

The Company, in order to ensure a fair treatment of all of the ODIRNANE holders, implemented a repurchase offer in France from 3 October to 7 October 2016 (inclusive), for a unit price of EUR 34.50 (including accrued interest) per ODIRNANE, being the price set out during the Repurchase Proposal. A total number of 2,274,766 ODIRNANE, representing around 40.6% of the ODIRNANE initially issued, were tendered to the repurchase offer.

The settlement of the ODIRNANE repurchased pursuant to the repurchase offer is expected on 13 October 2016.

The total number of ODIRNANE repurchased by the Company pursuant to the Repurchase Proposal and the repurchase offer amounts to 5,108,047 ODIRNANE, i.e. circa 91.2% of the ODIRNANE initially issued. Therefore, 494,193 ODIRNANE remain outstanding, representing circa 8.8% of the ODIRNANE initially issued.

The repurchased ODIRNANE will be cancelled in accordance with their terms and conditions and according to law.

The Company reserves the right to repurchase in the future ODIRNANE through market or off market transactions.

The Company also reserves the ability to exercise its right to early redeem, at its option, the remaining outstanding ODIRNANE, being less than 10% of the ODIRNANE initially issued, as provided under the terms and conditions of the ODIRNANE.

Assystem is an international group specialised in engineering. As a key participant in the industry for 50 years, Assystem supports its clients in developing their products and managing their capital expenditure throughout the product life cycle. Assystem employs 11,800 people worldwide and generated €908 million in revenue in 2015. Assystem S.A. is listed on Euronext Paris.

For more information please visit
Follow Assystem on Twitter: @Assystem


Philippe Chevallier
Deputy Chief Executive Officer & Chief Financial Officer
Tel.: +33 (0)1 55 65 03 10
Agnès Villeret
Tel.: +33 (0)6 83 28 04 15

CONTACTS Société Générale Corporate & Investment Banking

Convertible Sales & Trading

Jeff Biss

Tel. : +44 2075514417
Mob. : +44 7711167878
Equity Syndicate

Nishley Seegobin

Tel. :  +33 (0)1 42 13 37 24
Mob. :  +33 (0)6 78 47 18 12

Not for publication, release or distribution directly or indirectly in the United States, Canada, Australia or Japan. This press release is not an offer of securities, or a solicitation for purchase, subscription or sale of securities in the United States or in any other jurisdiction in which it would be unlawful to do so.


Proposed repurchase of ODIRNANE

No communication and no information in respect of the offer to buy the ODIRNANE may be distributed to the public in any jurisdiction where a registration or approval is required. No steps have been or will be taken outside of France in any jurisdiction where such steps would be required.

This press release does not constitute an invitation to participate in the repurchase of the ODIRNANE in any country in which, or to any person to whom, it is forbidden to make such an invitation in accordance with applicable laws and regulations. In particular, the ODIRNANE repurchase is not offered and will not be offered, directly or indirectly to the United States of America in any form or mean whatsoever. Persons in possession of this press release are summoned to inform themselves and to conform with all legal and regulatory restrictions.

This document constitutes an advertisement and not a prospectus.

No communication or other information related to this transaction or to Assystem may be transmitted to the public in a country in which any approval or registration is required. No steps to such end have been taken or will be taken by Assystem in any country in which such steps would be required (other than France).

This press release and the information contained herein do not constitute and cannot be construed as a public offer, an offer to sell or subscribe or a solicitation of an order to purchase or subscribe securities in any country, other than France.

This press release does not constitute an offer or a solicitation to sell or subscribe for securities requiring a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and Council dated November 4, 2003, as amended, including by Directive 2010/73/EU (together, the "Prospectus Directive", such expression including any relevant implementing measure in each member State of the European Economic Area).

With respect to the member states of the European Economic Area other than France (each a "Member State") having implemented the Prospectus Directive, no action has been or will be taken in order to permit a public offer of the securities which would require the publication of a prospectus in any Member State. In each Member State, the information contained herein is addressed solely to persons who are "qualified investors" within the meaning of the Prospectus Directive.

The securities mentioned in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, or sold in the United States in the absence of such registration or an applicable exemption from the registration requirement under the Securities Act. Assystem does not intend to register any portion of the planned offering in the United States or to conduct a public offering of securities in the United States.

This press release is neither an invitation nor an inducement to engage in investment activity for the purpose of Section 21 of the Financial Services and Markets Act 2000, as amended ("FSMA"). This press release is directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (iii) persons referred to in Article 49(2) (a) to (d) of the Order (high net worth entities, non-registered associations, etc.) and (iv) other persons to whom this document may be lawfully communicated (all persons listed in (i), (ii), (iii) and (iv) above being referred to as "Relevant Persons"). The securities of Assystem S.A. described herein are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, Relevant Persons. Any person who is not a Relevant Person must not act or rely on this document or any of its contents.

The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations. Persons physically located in such jurisdictions into which this press release is released, published or distributed must inform themselves about and comply with such laws or regulations.

This press release must not be published, released or distributed, directly or indirectly, in the United States, Australia, Canada or Japan.

ASSYSTEM: Repurchases of outstanding ODIRNANE

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: ASSYSTEM via GlobeNewswire